Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma

Oncologist

Volumn 19, Issue 9, 2014, Pages 917-918

  Bellmunt, Joaquim ^a,d   Suarez, Cristina ^b   Gallardo, Enrique ^c   Rodon, Jordi ^b   Pons, Francesc ^d   Bonfill, Teresa ^c   Beltran, Marta ^b   Moya, Irene ^c   Galtes, Susana ^d   Albanell, Joan ^d   Carles, Joan ^b  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; GEMCITABINE; SUNITINIB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG SAFETY; HUMAN; KIDNEY CARCINOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; THROMBOCYTOPENIA; ADULT; ADVERSE DRUG REACTION; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLUOROURACIL; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES; TREATMENT OUTCOME;

EID: 84906976089     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0072     Document Type: Article

References (0)